Cartherics raises over $15 Million in oversubscribed private financing round to advance cell therapy programs
Posted: 2 October 2024 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer and other diseases, is pleased to announce that it has successfully raised well over its target AU$15M…
First human vagus nerve recordings pinpoint cardiovascular signals
Posted: 2 October 2024 The team that first recorded vagus nerve signals in humans has isolated the electrical activity of individual neurones responsible for cardiovascular regulation. Published in The Journal of Physiology, the Monash University-led discovery paves the way…
Professor Emma Johnston AO appointed new Vice-Chancellor
Posted: 2 October 2024 University of Melbourne Chancellor, Jane Hansen AO, today announced the appointment of Professor Emma Johnston AO as the 21st Vice-Chancellor of the University of Melbourne. Professor Johnston is the first woman to be appointed…
$50 million for transformative multidisciplinary health and medical research
Posted: 2 October 2024 Ten outstanding and versatile research teams have collectively been awarded $50 million to support them in working together to address major problems in human health under the NHMRC’s 2024 Synergy Grants scheme. Synergy Grants support…
Melbourne’s Bionics Institute has been awarded AUD$4.8 million (USD $3.2 million) by an American charitable trust to fund research into the development of a world-first, personalised, electrical treatment for Crohn’s disease.
Posted: 2 October 2024 Finding new ways to prevent and treat Crohn’s disease is a key focus for New York-based organisation The Leona M. and Harry B. Helmsley Charitable Trust, which has committed to funding this groundbreaking research…
Congratulations to the 2024 Governor of Victoria Export Award winners
Posted: 2 October 2024 Advanced Technologies For outstanding international success in the field of information technology, digital technologies, software, hardware or digital services. This includes solutions utilising cloud‑based platforms, artificial intelligence, machine learning, Internet of Things, augmented reality,…
Bristol Myers Squibb announced that the U.S. FDA approved COBENFY
Posted: 2 October 2024 Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults. 1 COBENFY represents the first…
Pushing the ‘Missing Link’ in Non-animal Preclinical Drug Development Closer to Market
Posted: 1 October 2024 Supported by MTPConnect’s Researcher Exchange and Development within Industry (REDI) Fellowship program, Trajan Scientific and Medical and The University of Melbourne’s Dr Xumei Gao are progressing biomedical research technology for non-animal methods for drug development. Animals are extensively…
Platform Expansion: Gastric Cancer Diagnostic Test Update
Posted: 25 September 2024 Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: RHY) (“Rhythm” or the “Company”) is pleased to provide an update on its cancer diagnostics technology platform expansion program in gastric cancer. Rhythm has…
Cartherics enters agreements with UniQuest, The University of Queensland and The University of Sydney for advancing innovative cardiac cellular therapy
Posted: 25 September 2024 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has entered into a Technology Licence Agreement (TLA) with The University…
Study sheds light on how antibodies protect children from cerebral malaria
Posted: 25 September 2024 In a first-of-its-kind study, an international team of researchers has discovered how specific antibodies in young children protect against cerebral malaria, a life-threatening condition caused by the Plasmodium falciparum parasite, paving the way for…
One-two punch treatment delivers blood cancer knockout
Posted: 25 September 2024 A novel combination of two cancer drugs has shown great potential as a future treatment for patients with acute myeloid leukaemia (AML), one of the most common types of blood cancer. A new study by WEHI…
